Business · 09/12/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ILARIS Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ILARIS, a human biological product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →